Workshops & Symposia at the 2020 ACCP Annual Meeting are identified as being part of either the “Drug Development Track” (DDT), the “Therapeutic Areas of Applied Clinical Pharmacology Track” (TCP), the “Applied Clinical Pharmacology Techniques Track” (ATT), the “Innovations Track” (IT), the “Quantitative Track” (QT) or the “Basic Science of Clinical Pharmacology Track” (BT) to make it easier for Attendees to determine which courses they prefer to attend.

**WEDNESDAY, SEPTEMBER 9, 2020**

**Pre-meeting Workshop 1 | 1:00 – 4:30 PM | DDT**

Analysis & Reporting of QTc Prolongation Potential of New Drugs Using R Tools, Expectations & General Guidance for Regulatory Submissions

CO-CHAIRS: Ana Ruiz-Garcia, PharmD, PhD, Senior Principal Scientist I, Metrum Research Group LLC and Dhananjay D. Marathe, PhD, Principal Scientist, Quantitative Pharmacology & Pharmacometrics, Merck & Co Inc

**FRIDAY, SEPTEMBER 11, 2020**

**Pre-meeting Workshop 2 | 10:00 AM - 1:30 PM | DDT**

Individualized Drug Therapy: Maximally-precise Drug Therapy for Each Individual Patient, at the Bedside, in a Community Hospital Setting

CHAIR: Michael N. Neely, MD, Chief, Infectious Diseases, Director, Laboratory of Applied Pharmacokinetics & Bioinformatics, Children’s Hosp Los Angeles, Professor of Pediatrics & Clinical Scholar, Keck School of Medicine, Univ of Southern California

**TUESDAY, SEPTEMBER 15, 2020**

**Pre-meeting Workshop 5 | 8:00 AM - 12:00 PM | DDT**

Innovative Drug Development in Asia: Challenges & Opportunities

CO-CHAIRS: Haiyan Li, MD, Peking Univ Third Hosp, China and Gailing Li, PhD, Janssen Research & Development LLC

**MONDAY, SEPTEMBER 21, 2020**

**Symposium 1 | 10:00 - 11:30 AM | DDT**

Strategies & Considerations for the Assessment of Relative Dose Intensity in Oncology Drug Development

CHAIR: Divya Samineni, PhD, Scientist, Genentech Inc

**Symposium 2 | 10:00 AM - 1:30 PM | TCP**

What is the Right Dose in Cancer Patients With Hepatic Dysfunction? Considerations in the Translation of Pharmacokinetic Studies from Clinical Trial to Clinic

CO-CHAIRS: Nithya Srinivas, PhD, Research Investigator, Incyte Corp and Islam R. Younis, PhD, Director, Astellas Pharma US Inc

**Symposium 3 | 12:00 - 1:30 PM | TCP**

The Race to Develop New Targeted Therapies for Children With Brain Tumors: Where Do We Go?

CO-CHAIRS: Gilbert J. Burckart, PharmD, Associate Director, Pediatrics, US Food & Drug Administration and Clinton F. Stewart, PharmD, Member & Interim Director, Pharmaceutical Sciences, St Jude Children’s Research Hosp

**Symposium 4 | 2:00 - 3:30 PM | TCP**

Pediatric Renal Function: Why We Still Need to Explore Renal Maturation & Its Impact on Drug Therapies

CO-CHAIRS: Jian Wang, PhD, Associate Director, Drug Evaluation IV, CDER, US Food & Drug Administration and Catherine MT Sherwin, PhD, Professor & Vice Chair for Research, Director, Pediatric Clinical Pharmacology, Pediatrics, Wright State Univ Boonshoft School of Medicine, Dayton Children’s Hosp

**Symposium 5 | 2:00 - 3:30 PM | DDT**

Clinical Pharmacology in Anti-infective Drug Development

CHAIR: Amit Somani, PhD, Clinical Pharmacology Reviewer, US Food & Drug Administration

**Symposium 6 | 4:00 - 6:00 PM | IT**

Innovative Technologies in Patient-centric Drug Development: Promises & Challenges

CO-CHAIRS: Anuradha Ramamoorthy, PhD, Policy Lead, Clinical Pharmacology, CDER, US Food & Drug Administration and Leslie Dickmann, PhD, MPH, Program Director, School of Pharmacy, Univ of Wisconsin Madison
### TUESDAY, SEPTEMBER 22, 2020

**Symposium 7 | 10:00 AM - 12:00 PM | DDT**  
CO-CHAIRS: Olanrewaju Okusanya, PharmD, MS, Team Leader, US Food & Drug Administration and Vadrin Pierre, PharmD, Director, Clinical Pharmacology, EMD Serono Inc

**Symposium 8 | 10:00 - 11:30 AM | ATT**  
Learning Health Systems: Leveraging Synergies Between Pharmacometrics & Pharmacoepidemiology for Efficient Healthcare Delivery  
CO-CHAIRS: Ayyappa Chaturvedula, PhD, Associate Professor, Pharmacotherapy, Univ of North Texas Health Science Ctr and Navin S. Goyal, PhD, Director, Clinical Pharmacology Modeling & Simulation, GlaxoSmithKline plc

**Symposium 9 | 12:00 - 1:30 PM | DDT**  
Building Bridges: Combination of Product Drug/Device Development With Biologics  
CO-CHAIRS: Jocelyn H. Leu, PharmD, PhD, Scientific Director, Janssen Research & Development LLC and Yow-Ming Wang, PhD, Associate Director, Biosimilars & Therapeutic Biologics, Clinical Pharmacology, CDER, US Food & Drug Administration

**Symposium 10 | 12:00 - 1:30 PM | QT**  
What's Next in Model-informed Drug Development? Joined Pharmacometrics & Epidemiological (Real-world Data) Approaches  
CHAIR: Yan Xu, MD, PhD, Director, Clinical Pharmacology & Pharmacometrics, Janssen Research & Development LLC

**Symposium 12 | 2:00 - 3:30 PM | TCP**  
The Opioid Overdose Epidemic: Trends, Harms & Treatment  
CHAIR: Sam Harirforoosh, PharmD, PhD, Professor, Gatton Coll of Pharmacy, East Tennessee State Univ

**Symposium 13 | 2:00 – 5:30 PM | ATT**  
Patient-reported Outcomes in Drug Development & Clinical Practice  
CHAIR: Barbara Ameer, PharmD, MBA, Adjunct Associate Professor, Medicine, Rutgers Robert Wood Johnson Medical School

### WEDNESDAY, SEPTEMBER 23, 2020

**Symposium 14 | 10:00 AM - 12:00 PM | QT**  
Applying Pharmacometrics to Precision Dosing in the Lifecycle of Long-acting Injectable Products: Drug Development, Regulatory Approval & Clinical Practice  
CO-CHAIRS: Hong Lu, PhD, Scientific Director, Takeda Pharmaceuticals USA Inc and Lanyan (Lucy) Fang, PhD, Associate Director, Quantitative Methods & Modeling, Research & Standards, Generic Drugs, Ctr for Drug Evaluation & Research, US Food & Drug Administration

**Symposium 15 | 10:00 - 11:30 AM | DDT**  
Applying Quantitative Clinical Pharmacology to Support the Drug Development of T cell-redirecting Bispecific Antibodies  
CO-CHAIRS: Weirong Wang, MD, PhD, Scientific Director, Janssen Research & Development LLC and Xiling Jiang, PhD, Staff Fellow, US Food & Drug Administration

**Symposium 17 | 12:00 - 1:30 PM | TCP**  
Innovative Approaches in the Use of Exposure-Response in Therapeutic Proteins to Support Pediatric Extrapolation  
CO-CHAIRS: Robert M. Nelson, MD, PhD, Senior Director, Pediatric Drug Development, Johnson & Johnson and Jocelyn H. Leu, PharmD, PhD, Scientific Director, Janssen Research & Development LLC

**Symposium 18 | 12:00 - 1:30 PM | BT**  
Partial Area Under the Curve Analysis in Generic & New Drug Development  
CO-CHAIRS: Liang Zhao, PhD, Director, Quantitative Methods & Modeling, Research & Standards, Generic Drugs, Ctr for Drug Evaluation & Research, US Food & Drug Administration and Keith Gallicano, PhD, Chief Scientific Officer, Novum Pharmaceutical Research Svcs

**Symposium 19 | 2:00 – 3:30 PM | DDT**  
Bacteriophage as a New Weapon to Fight Drug-resistant Bacteria  
CHAIR: Stephan Schmidt, PhD, Certara Professor, Associate Professor & Director, Ctr for Pharmacometrics & Systems Pharmacology, Pharmaceuticals Lake Nona, Univ of Florida

**Symposium 20 | 2:00 - 6:00 PM | BT**  
Transporter-mediated Drug-Drug Interactions, Current Status & Future Perspectives: An ACCP/ISSX Jointly-sponsored Symposium  
CHAIR: Yanke Yu, PhD, Director, Clinical Pharmacology, Pfizer Inc

**Symposium 21 | 4:00 – 5:30 PM | DDT**  
Beyond Pharmacokinetic Equivalence: Assessment of Pharmacodynamic Similarity in Biologic & Small Molecule Drug Development  
CO-CHAIRS: Peijuan Penny Zhu, PhD, Associate Director, Pharmacometrics, Janssen Research & Development LLC and Ping Ji, PhD, Biologics Lead, US Food & Drug Administration